Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 175 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Small Cell Lung Cancer Limited Stage Clear all
Completed Phase 2 Interventional

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00004176
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Sep 30, 2026, 6:26 PM EDT
Not listed Phase 2 Interventional

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

NCT00643318
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
CyberKnife Stereotactic Radiosurgery
Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Fresno, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Sep 30, 2026, 6:26 PM EDT
Active, not recruiting Phase 1 Interventional

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

NCT05353439
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Tazemetostat Hydrobromide, Topotecan Hydrochloride
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Newport Beach, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 30, 2026, 6:26 PM EDT
Completed No phase listed Observational

Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

NCT01517971
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 30, 2026, 6:26 PM EDT
Terminated Phase 2 Interventional Results available

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

NCT00544674
View directory record Official record
Conditions
Lung Cancer
Interventions
PR104, F-18-fluoromisonidazole
Drug · Other
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Tucson, Arizona • Beverly Hills, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 30, 2026, 6:26 PM EDT
Completed No phase listed Observational

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

NCT01294280
View directory record Official record
Conditions
Lung Cancer
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Sep 30, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NCT03794544
View directory record Official record
Conditions
Resectable, Early-stage, NSCLC
Interventions
Durvalumab, Oleclumab, Monalizumab, Danvatirsen
Drug · Combination Product
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 102 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
La Jolla, California • Fort Myers, Florida • Leesburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 30, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Results available

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

NCT00554463
View directory record Official record
Conditions
Lung Cancer
Interventions
Filgrastim, Pegfilgrastim, Etoposide, Cisplatin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
14
States / cities
Gainesville, Florida • Miami Beach, Florida • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 30, 2026, 6:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

NCT05191797
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Interventions
Bomedemstat, Atezolizumab
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 30, 2026, 6:26 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

NCT02038699
View directory record Official record
Conditions
Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
Interventions
ONC201
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Sep 30, 2026, 6:26 PM EDT
Active, not recruiting Phase 2 Interventional

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

NCT06773910
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
BMS-986489, Durvalumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
34
States / cities
Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 6:26 PM EDT
Recruiting Phase 3 Interventional

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
27
States / cities
Fresno, California • Glendale, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 30, 2026, 6:26 PM EDT
Completed Not applicable Interventional

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

NCT00433407
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
trastuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 30, 2026, 6:26 PM EDT
Completed Early Phase 1 Interventional Results available

Neoadjuvant Itraconazole in Non-small Cell Lung Cancer

NCT02357836
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Itraconazole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 30, 2026, 6:26 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

NCT04025879
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 30, 2026, 6:26 PM EDT
Terminated Phase 2 Interventional Results available

Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer

NCT00527982
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
Celecoxib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Sep 30, 2026, 6:26 PM EDT
Terminated Phase 1 Interventional

Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

NCT00866086
View directory record Official record
Conditions
Lung Cancer
Interventions
questionnaire administration, computed tomography, radiation therapy treatment planning/simulation
Other · Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 30, 2026, 6:26 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Sep 30, 2026, 6:26 PM EDT
Terminated No phase listed Observational

Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

NCT03553550
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
biospecimen collection
Other
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 30, 2026, 6:26 PM EDT
Terminated Phase 2 Interventional Results available

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

NCT03995667
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Questionnaire Administration, Tumor Treating Fields Therapy
Other · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
22 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 30, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Results available

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

NCT01262560
View directory record Official record
Conditions
Dysphagia, Lung Cancer, Pain, Esophagitis
Interventions
Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
59
States / cities
Mobile, Alabama • San Francisco, California • Stanford, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 30, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

NCT00101192
View directory record Official record
Conditions
Cervical Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
18
States / cities
Burbank, California • Los Angeles, California • Savannah, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 30, 2026, 6:26 PM EDT
Terminated Phase 2 Interventional Results available

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

NCT03968419
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Canakinumab, Pembrolizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
La Jolla, California • Kansas City, Kansas • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 30, 2026, 6:26 PM EDT
Completed Not applicable Interventional Results available

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

NCT01209520
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
Interventions
Cisplatin, Carboplatin, Paclitaxel, Vidaza, Tumor Specimen for Methylation Analysis, Blood Sample for Methylation Analysis, Vinorelbine, Docetaxel, Pemetrexed
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Sep 30, 2026, 6:26 PM EDT